The L5 antigenic determinant was previously suggested to be a carbohydrate epitope present on murine cell recognition molecules in the developing brain and to be an early neural marker in the chick embryo. Here, we show that L5 immunoreactivity is associated with complex-type N-glycosidic oligosaccharides. To identify the carbohydrate structure recognized by the L5 antibody, we investigate its binding to N-linked oligosaccharides derived from L5 glycoproteins and to known glycans. Results of mass spectrometric analyses of L5-positive neoglycolipids prepared from L5 glycoproteins are consistent with those for N-glycans containing a 3-fucosyl N-acetyllactosamine sequence. We also investigate L5 binding to structurally defined, lipid-linked oligosaccharides based on the blood group type I and II backbones. Chromatogram binding assays, ELISA, and inhibition studies show that the antibody reacts strongly with carbohydrate chains presenting the 3-fucosyl N-acetyllactosamine sequence [Lewisx(Lex) or X-hapten] also recognized by anti-SSEA-1 and anti-CD15. Histochemical studies with different antibodies recognizing the L&< sequence show partially overlapping patterns of immunoreactivity during early neural development in the chick embryo. Therefore, we suggest that the epitope recognized by L5 antibody is closely related to those for anti-SSEA-1 and anti-CD15. Key Words: CD1 5-Chick embryo-L5_Lewisx_Neural induction-SSEA-1. J. Neurochem. 66, 834-844 (1996).
In the early chick embryo, the L5 antigen appears to be expressed initially by cells that are competent to respond to neural inducing signals. During neural induction it becomes rapidly restricted to and up-regulated in the developing nervous system (Roberts et al., 1991; Streit et al., 1995) . Hensen's node (the source of neural inducing signals), and hepatocyte growth factor/scatter factor, which is expressed in the node, are both able to maintain and enhance L5 expression in areas of the embryo that would otherwise lose immunoreactivity rapidly. Furthermore, the L5 antibody interferes with neural induction in vivo (Roberts et al.. 1991) , suggesting that the L5 epitope itself plays a role during early neural development.
Initial studies indicated that the L5 antigenic determinant is a carbohydrate, as immunoreactivity of the murine cell recognition molecule LI is lost after digestion with a preparation of endoglycosidase F (Streit et al., 1990) . To gain insight into the mechanisms of how the L5 antigen participates in neural development, we have investigated the antigenic determinant recognized by the antibody. We report that the L5 antibody recognizes an epitope closely related to those for anti-SSEA-I and anti-CD 15.
MATERIALS AND METHODS

Antibodies
The rat monoclonal antibody L5 was prepared and purified from cultLire supernatant as described previously (Streit et al.. 1990 ). The mouse 1gM anti-SSEA-l antibody, clone MC-480 (Solter and Knowles, 1978) , was purchased from the Developmental Studies 1-lybridoma Bank and the mouse 1gM AC4 (Dodd and Jessell. 1985) was a kind gift from Dr. T. M. Jessell. In ELISA, we used alkaline phosphatase-(Dianova, Hamburg, Germany) or horseradish peroxidase (HRP)-coupled (Calbiochem) antibodies to rat 1gM. The latter were also used as secondary antibodies in chromatogram binding assays and immunohistochemistry with L5. For immunohistochemical staining with anti-SSEA-I and AC4, HRP-coupled antibodies to mouse 1gM were purchased from Sigma.
Glycoproteins and glycopeptides
LI glycoprotein (Rathjen and Schachner, 1984) was purified from the soluble fraction of early postnatal mouse brain and was kindly provided by Dr. B. Fuss (UCLA, U.S.A.).
L5-positive glycoproteins from mouse brain were purified as described previously (Streit et al., 1990) . [5 glycoproteins were isolated from freshly frozen pig brain using the following procedure. Brain tissue (50 g) was homogenized in 75 ml 50 mM Tris-HC1, 150 mM NaCI, 1 mM EDTA, pH 8.0, containing the following protease inhibitors: trypsin inhibitors from soybean (10 pg/mI) and turkey egg white (20 pg/mI), iodoacetamide (0.1 mM), phenylmethylsulfonyl fluoride (I mM) , N-a-p-tosyl-i.-lysine chloroniethyl ketone (TLCK; 10 pg/mI), N-tosyl-L-phenylalaninc chloromethyl ketone (TPCK; 10 pg/mI), pepstatin (1 pM), and leupeptin (1 pM). Chloroform/methanol 1:2 (vol/vol) (900 ml) was added and the suspension stirred for 1-2 h at room temperature. The pellet was recovered by filtration through Whatman 3 MM filters, washed with ethanol twice, and dried yielding -5 g of delipidated protein (10% of starting wet weight of the tissue). The proteins were then soluhilized in 20 mM Tris-HCI, 1 mM EDTA, ISO mM NaCI, 1% deoxycholate, pH 8.0, containing the protease inhibitor cocktail described above for 4 h at 4°C. Insoluble material was removed by centrifugation at 100,000 g. The supernatant was passed over a Sepharose 4B column connected in series with an L5 monoclonat antibody affinity column (Streit et al., 1990 ) equilibrated in 20 mM Tris-HCI, 150 mM NaCI, 0.1% deoxycholate, pH 7.6. After washing with 5 volumes each of 20 mM Tris-HCI, 450 mM NaCI, 0.1% deoxycholate, pH 7.6, and equilibration buffer, the L5 monoclonal antibody column was eluted with 100 mM diethanolamine, 20 mM Tris, I mM EDTA, 0.1% deoxycholate, p1-1 11.5. The eluate was immediately neutralized with I M Tris-HC1, pH 6.8, extensively dialyzed against water and freeze dried. This procedure resulted in -50 pg of purified L5 glycoproteins.
Enzymatic deglycosylation of affinity-purified L5 glycoproteins with endo-~-N-acetylglucosaminidaseD from Diplococcus pneumomae (EC 3.2.1.96; 2 mU! 10 pg ofprotein).
peptide N-glycohydrolase F free endo-~-N-acetylgIucosami- Glycopeptides from Thy-I glycoprotein were obtained as described (Parekh et al.. 1987 ) and were kindly provided by Dr. A. Williams (Oxford, U.K.).
RNase B, hen ovalbumin, fetal calf serum fetuin. human transferrin, human immunoglobulin C, and a'-acid glycoprotein were purchased from Sigma.
Oligosaccharides
Lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT).
lacto-N-fucopentaose I (LNFP-I). Iacto-N-fucopentaose II (LNFP-II), and lacto-N-fucopentaose III (LNFP-lll), lacto-N-difucohexaose I (LNDFH-l), lacto-N-neodifucohexaose II (LNnDFH-II), lacto-N-difucohexaose II (LNDFH-ll) were purchased from Dextra Laboratories (Reading. U.K.); fuco-p -lacto-N-hexaose (FpLNH). monofucolacto-N-hexaose (MFLNH), and difucolacto-N-neohexaose (DFLNnH) were from Biocarb Chemicals (Lund. Sweden). Lewis'-trisaccharide (Le'Tni) was from Dextra. Lewis-tnsaccharide (LeTri) was a gift from Prof. A. Lubineau (Orsay. France); sialyl Lewis'-pentasaccharide (3SLNFP-ll) was a gift from Dr. G. Strecker (Lille. France); sulphated Lewis'-tetrasaccharide (SuLe'Tetra) was a gift from Dr. K. C. Nicolaou (Scripps Institute, California. U.S.A.).
N-linked oligosaccharides were obtained from glycoproteins by hydrazinolysis; these included RNase B [high mannose-type oligosaccharides (Liang et al., 1980) J, transfernin Ibiantennary complex-type oligosaccharides (Spik et al., 1975) J, fetuin I mainly triantennary complex-type oligosaccharides (Takasaki and Kohata. 1986 )1, a 1-acid glycoprotein I tn-and tetraantennary complex-type oligosaccharides including outer chains containing the sialyl Lewis' (Le') sequence (Yoshima et al., 1981 ) I. ovalbumin [hybrid-type oligosaccharides (Yamashita et al., 1983) ], human IgG [hiantennary complex-type oligosaccharides with and without bisecting N-acetylglucosamine (Mizuochi et al.. 1982) ], L5 glycoproteins (multiantennary complex-type), and Thy-I glycopeptides Isite I, Asn~,high mannose-type and site 2, Asn 74, biantennary complex-type oligosaccharides containing fucose residues (Parekh ci al., 1987; Williams et al., 1993) 1. Asialo oligosaccharides were prepared by digestion with Arthrohacter ureaJcicien.s neuraminidase (Boehringer Mannheim) using conditions suggested by the supplier after they were released by hydrazinolysis. Neutral oligosaccharides were obtained after passing over either a DEAE A-25 Sephadex column (Pharmacia. Milton Keynes, U.K.) or through a double-bed column of AGSOW Xl 2 arid AG3 4A ion-exchange resins (Bio-Rad, Hemel Hempstead. U.K.). Biantennary N-glycosidic oligosaccharides containing Le' on one antenna (MonoLe') or two antennae (DiLe') were prepared from a recombinant glycoprotein and were kindly provided by Dr. D. Cumming (Genetics Institute, Boston, MA, U.S.A.).
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Lipid-linked oligosaccharides
Neoglycolipids were prepared by conjugation of oligosaccharides to L-I ,2-dihexadeeyl-sn-glycero-3-phosphoethanolamine (DHPE; Fluka Chemicals Ltd., Cillingham, U.K.) and purified according to Feizi et al. (1994) . The glycosphingolipids 3 '-sialyllacto-N-fucopentaose Ill ceramide (3SLNFP-III) and 6 '-sialyllacto-N-fucopentaose III ceramide (6SLNFP-EII) were synthesized chemically, and were gifts from Drs. A. Hasegawa and M. Kiso (Gifu University, Japan).
Chromatogram binding assay
Neoglycolipids and glycolipids were chromatographed on aluminum-backed silica gel 60 high-performance TLC plates (Merck, Poole, U.K.) using chloroform/methanol/water solvent mixtures by volume as indicated in the figure legends.
Lipids were visualized by pnimulin staining (Feizi et al., 1994) before overlay assays. Dried plates were treated with 0.01% Plexigum P-28 in n-hexane (Cornelius Chemical Co., Romford, U.K.) for 1 mm, air dried again, and blocked in 3% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), pH 7.4, for 2 hat room temperature. The plates were then incubated with monoclonal LS antibody diluted 1:50 in 1 % BSA in PBS for another 2 h at room temperature, washed three times in PBS for 5 mm each, and incubated in HRPcoupled secondary antibody (1:2,000) for one more hour.
After washing, the plates were processed for detection with ECL (Amersham International plc, Amersham, U.K.) according to the manufacturer's instructions; in general, exposure times of 15-30 s were used.
ELISA and inhibition assays
LS glycoproteins (20 pg/mI in 100mM NaHCO,) before and after enzymatic deglycosylation were coated on flexible microtitre plates (Falcon, Cockeysville, MD, U.S.A.) overnight at 4°C.After blocking for 2 h with 3% BSA in PBS, the wells were washed briefly in PBS, incubated with L5 monoclonal antibody (1:50) diluted in 1% BSA in PBS for 2 h, washed five times in PBS, and incubated with secondary antibody coupled to alkaline phosphatase (1:5.000) for another hour. Color reaction was performed with 1 mg/mI pnitrophenol phosphate (Sigma) in 20 mMTris-HC1, pH 9.6, 0.5 mM MgCI 2, and 0.5 mM ZnCI, and absorbance measured at 405 nm.
Neoglycolipids were dissolved in methanol at concentrations indicated in the figure legends, applied to flexible microtitre plates, and air dried. Incubation steps were performed as described above, except in some cases where HRP-coupled secondary antibodies were used. In these cases the colour reaction was developed with 4 mM o-phenylenediamine, 0.004% H,O, in 20 mM citric acid, and 50 mM Na2HPO4, pH 5.0, and measured at 492 nm.
Appropriate antibody concentrations for inhibition studies were determined by titration of LS antibody binding to constant amounts of coated neoglycolipids or proteins. Concentrations giving 60-70% binding were chosen. For inhibition assays, the antibody was preincubated for 2 h with soluble oligosaccharides before ELISA, which was then performed as described above.
Mass spectrometry
The L5-positive neoglycolipid band derived from LS glycoproteins was cut out from the TLC plate with its aluminum backing and subjected directly to liquid secondary ion mass spectrometry (LSIMS) after addition of solvent (3 pA; chloroform/methanol/water, 25:25:8 by volume) and matrix (tetramethylurea/diethanolamine/m-nitrobenzyl alcohol, 2:2:1 by volume). A negative ion mass spectrum was obtained at 1,000 resolving power on a VG Analytical ZAB2-E mass spectrometer with a DEC 3300/Opus data system using a caesium gun operated at 35 keV and emission current of 0.5 pA.
Whole-mount immunostaining of embryos
Fertile hens' eggs were obtained from Spafas (Massachusetts) and incubated at 38°C Lintil they had reached the desired stage of development. Stages were assessed according to Hamburger and Hamilton (1951) . Whole-mount immunostaining was performed as described previously (Streit et al., 1995) .
RESULTS
Demonstration of L5 immunoreactivity on complex-type N-glycosidic oligosaccharides
When total L5 glycoproteins isolated from pig brain are digested with endoglycosidases with different specificities, we find that L5 immunoreactivity in ELISA is markedly decreased after digestion with peptide Nglycosidase F (data not shown) showing a reduction in antibody binding to <10% of that observed with the untreated glycoproteins. This is consistent with our previous results using endoglycosidase F containing peptide N-glycosidase F (Streit et al., 1990 ). In contrast, digestion with peptide N-glycosidase F free endoglycosidase F has no effect. Digestion with endoglycosidases D or H, or with chondroitinase ABC, does not alter L5 immunoreactivity. There is a modest increase of antibody binding ('-15%) after neuraminidase treatment. These results are consistent with L5 immunoreactivity being associated predominantly with complex-type N-glycosidic oligosaccharides that are neuraminidase resistant and partly masked by sialic acid.
Evidence for a relationship between L5 and Le'
To analyze L5-positive oligosaccharides further, N-linked oligosaceharides were released from [5 glycoproteins by hydrazinolysis. Neoglycolipids were prepared from the neutral and acidic oligosaccharide fractions and tested for [5 antibody binding by the chromatogram overlay assay (Fig. I) . No immunoreactivity is associated with the acidic oligosaccharides (not shown), but two prominent immunoreactive bands are detected in the neutral fraction of oligosaccharides derived from pig brain glycoproteins, and one prominent and one weakly positive band in a similar fraction derived from mouse brain. The chromatographic mobilities of the main immunoreactive neoglycolipids from L5 glycoproteins are in the same range as those derived from complex-type biantennary asialooligosacchanide chains from transferrin. Two immunoreactive bands are also observed in neutral oligosacchanides of a1-acid glycoprotein (see below).
When analyzed by LSIMS, the main immunoreacfive band derived from munine L5 oligosacchanides 2 in A; lanes 1-4 in B) , the chromatograms were probed with L5 antibody (lanes 1' and 2' in A; lanes 1 '-3' in B). There are two major L5 immunoreactive bands in oligosaccharides derived from pig brain (A: lane 1'), and one prominent and one very weak (arrowhead) L5 immunoreactive band in those derived from mouse brain (B: lane 3'). Neoglycolipids from transferrin (A: lanes 2, 2'; B: lanes 1, 1') and cs 1-acid glycoprotein (B: lanes 2, 2') were applied for comparison of mobility and L5 immunoreactivity. Lane 4 in B shows neoglycolipids derived from murine L5 glycoproteins separated by preparative TLC; the area corresponding to the main L5 positive band (square bracket) was analyzed by mass spectrometry. Double-headed arrows indicate the origin.
( Fig. I) yielded a quasimolecular ion M-H at tn/z 2,620 and an ion resulting from dehydration (m/z 2,602); the latter is characteristic of a lipid-linked Nglycosidic oligosacchanide with a core N-acetylglucosamine (Mizuochi et al., 1989; Feizi et al., 1994) . The deduced composition for these ions is five N-acetylhexosamines, four hexoses, and two deoxyhexoses, which is consistent, for example, with the following sequence:
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Man-GIcNAc-GlcNAc glycoproteins lacking Le'-related sequences, i.e., human IgG, ribonuclease B, and fetuin ( Fig. 2) and ovalbumin (not shown).
Structural requirements for L5 antibody binding
We performed chromatogram binding assays using a series of structurally defined, lipid-linked oligosaccharides based on GaLBl-4GlcNAc and Ga~8l-3GIcNAc, which constitute backbones of the Le' and Le antigens, respectively (Table I, Fig .3 ). Among the oligosaccharide sequences examined, a marked preference is revealed for the [Cx antigen sequence; L5 antibody binds strongly to the Lex~activeLNFP-III and LNnDFH-IT but not to the nonfucosylated backbone LNnT (Fig. 3A) . Under the standard assay condition using 50 pmol of neoglycolipid per lane, there is almost undetectable binding to the Lea active LNFP-II (Fig. 3A) . This observation is confirmed in ELISA using immobilized LNFP-II (Fig. 4A ) and in inhibition assays (see below).
In chromatogram binding assays, no L5 immunoreactivity is observed with the Le 5 active sequence LNDFH-I and the blood group H-active sequence LNFP-I, nor with FpLNH, which has an internal Le°s equence (Fig. 3A and Table 1 ). Furthermore, the sialyl [NFP-II (3SLNFP-Il), sialyl LNFP-III (3 and 6SLNFP-I II), and SuLe 'Tetra are L5 negative (Table   1 ). These data suggest that the L5 antibody recognizes terminal Lex sequences and that binding is inhibited by additional moieties attached to the terminal galactose.
Further details of L5 specificity are obtained by comparison of various branched oligosaceharides in chromatogram binding assays (Fig. 3B) . The intensity of L5 antibody binding to the branched DFLNnH sequence is equivalent to that to LNFP-III, whereas L5 binding to MFLNH and to the Mono-and DiLex oligosaccharides of N-glycosidic-type is weaker than to LNFP-lll, which indicates a preference for fucose 3-linked to the terminal Ga~3l-4GlcNAc~l-3se-quence rather than to the Gal@l-4GlcNAc~l-6or the GaL8I-4GIcNAcfII-2 sequences.
An N-glycosidic oligosaccharide of this type, with a bisecting N-acetylglucosamine, would be predicted to be resistant to digestion by endoglycosidase F (Trimble and Tarentino, 1991) .
A relationship of the L5 epitope to Lex is suggested by the results of chromatogram binding experiments with neoglycolipids from several N-glycosylated proteins (Fig. 2) . The L5 antibody reacts with neoglycolipids derived from asialo~1 -acid glycoprotein, which contain complex-type tn-and tetraantennary oligosaccharides with the Lex sequence in their outer chains (also see Fig. I ). It also recognizes neoglycolipids derived from complex-type oligosaccharides containing outer arm fucose at Asn 74 of Thy-I but not those of oligomannose-type from Asn23. The antibody does not bind to oligosaceharides derived from other
FIG. 2.
[5 antibody binding to N-glycosidic, complex-type oilgosaccharides containing fucose. N-linked oligosaccharides were released from glycopeptides derived from Asn23 (lanes 1, 1') and Asn74 (lanes 2, 2') of Thy-i glycoprotein, human lgG (lanes 3, 3'), RNase B (lanes 4, 4'), fetuin (lanes 5, 5'), and a 1-acid glycoprotein (lanes 6, 6'); after desialylation, neutral oilgosaccharides were linked to lipids and resolved by TLC (solvent system, chloroform/methanol/water 55:45:10). Double-headed arrow indicates origin. After primulin staining (lanes 1-6), chromatograms were probed with [5 antibody (lanes 1 '-6'). The antibody binds strongly to neoglycolipids derived from Asn 4 Thy-i and a 1-acid glycoprotein. Oligosaccharidcs were conjugated to DHPE except for 3SLNFP-IlI and 6SLNFP-IlI, which were used as chemically synthesized glycosphingolipids; then they were separated by TLC and probed with L5 antibody. Binding is indicated by the following: -. no binding at 50-500 prnol/lane; (+), negligible binding at 50-100 pmol/lane but unequivocal binding at higher levels; +. moderate binding: ++, medium binding; and +++, strung binding at 50-100 pniol/lane. The Le°Trineoglycolipid, however, does not react with L5 antibody under the assay conditions ( Fig. 3A and Table I ); this may be due to the chemical modification of the N-acetylglucosamine (ring opening) that results from linkage to the lipid (Stoll et al., 1988) . In contrast, free LexTri is consistently more active than the pentasaccharide LNFP-III in the inhibition experiments performed in ELISA using immobilized LNFP-IIl (Fig 4B) and L5-positive glycoprotein LI (Fig. 4C ). In the same assay, the free oligosacchanide [NFP-Il and Le'Tri are very poor inhibitors of L5 binding (Fig. 4B) . 3-Fucosyllactose is '-30 times less potent as an inhibitor compared with [e°, indicating the importance of the N-aeetylglucosamine. These re-sults support the notion that the L5 antibody reacts with the Lex sequence, as present on the defined structures tested, and on the glycoprotein LI and only shows negligible affinity for Le°-acti ye sequences.
Expression of Le' in the chick embryo
We compared the patterns of immunoreactivity of the L5 antibody with those of two other antibodies known to recognize the Lex sequence, anti-SSEA-l (Solter and Knowles, 1978; Gooi et al., 1981) and AC4 (Dodd and Jessell, 1985) , by whole-mount immunostaining of chick embryos (Fig. 5) . All three antibodies give identical staining patterns at stages 3-4~ (Fig. SA, D, and G) . At later stages of development, the three antibodies stain the elevating neural plate and forming neural tube strongly (Fig. 5B, C, E , F, H, and I). However, some differences can be seen elsewhere at these stages. L5 immunoreactivity is confined to the developing neural tissue; but anti-SSEA-I and AC4, in addition, stain the developing area vasculosa where blood vessel formation begins, and the primordial germ cells (which can also be identified by alkaline phosphatase staining; Fig. 5K and L) . This is consistent with a previous report (Yoshinaga et al.. 1991 ) that SSEA-1 is a marker for primordial germ cells in the mouse embryo.
DISCUSSION
In this study we present evidence that the L5 antibody recognizes the blood group-related antigen Lewis' (also termed Le' or X-hapten), as do antibodies anti-SSEA-l and anti-CD15. In overlay assays and ELISA, the [5 antibody binds strongly to neoglycolipids prepared from oligosaccharides that present the terminal Le' sequence, such as N-glycosidic chains derived from glycoproteins or LNFP-III. In inhibition studies, LexTri is shown to be the most potent inhibitor of L5 antibody binding to immobilized LNFP-IlI or to L5-positive glycoproteins such as Ll. The binding experiments allow the following conclusions to be drawn: First, fucosylation of the subterminal N-acetylglucosamine and the presence of an unsubstituted terminal galactose are essential features for antibody recognition, because nonfucosylated structures, and those with modification of the galactose with additional fucose, sialic acid or sulphate, and internal Gal,@l-4 ( Fuca 1-3)GlcNAc sequences are all L5 negative. This is further supported by the fact that neuraminidase digestion of brain-derived L5 glycoproteins increases their [5 immunoreactivity, probably by unmasking Le' determinants. Second, N-acetylglucosamine appears to be another important component of the epitope, because in inhibition experiments 3-fucosyllactose proves to be a relatively poor inhibitor of L5 antibody binding. Third, Le xTni appears to comprise the entire antigenic determinant with none of the inter-nal saccharides (as present in LNFP-III) being involved, because the trisaccharide is the most potent inhibitor of L5 antibody binding to neoglycolipids and glycoproteins. In this respect, the L5 antibody resembles anti-SSEA-1 and differs from several CD1S antibodies that are more strongly inhibited by LNFP-III than by Le 'Tn (Gooi et al., 1985) . The results of mass spectrometric analyses of L5-positive neoglycolipids derived from L5 glycoproteins isolated from brain support the above conclusions.
We find a very weak interaction of the L5 antibody with the type 1 structure LNFP-II, an isomer of LNFP-III. Moreover, inhibition studies show that neither Le°-Tn nor LNFP-Il interfere with L5 antibody binding to LNFP-III in a concentration-dependent manner. We therefore suggest that the Le' determinant is likely to represent the L5 epitope as it is presented on glycoproteins. The stronger binding to LNFP-III (which con- The Le' epitope was shown to be an abundant component of the N-linked glycans of rat brain, where it occurs mainly in the sialylated form (Krusius and Finne, 1978) . The slight increase in L5 reactivity after neuraminidase treatment may suggest that this epitope is only partly sialylated in the L5 glycoproteins.
The Lex antigen has attracted much attention for some years as its expression is highly regulated during development and because it appears to be involved in a variety of cell interactions. Le' constitutes the stagespecific embryonic antigen 1, SSEA-l (Gooi et al., 198 I ), which appears in the eight-to 16-cell stage of the mouse embryo (Solter and Knowles, 1978; Pennington et al., 1985; Fenderson et al., 1986) , where it, or a related sequence, may be involved in compaction of the blastomeres (Bird and Kimber, 1984; Fenderson et al., 1984; Rastan et al., 1985) . Whether this is mediated by a lectin-oligosaccharide interaction as originally proposed (Gooi et al., 1981; Rastan et al., 1985) , or a carbohydrate-carbohydrate interaction (Eggens et al., 1989; Hakomoni, 1992) , has not yet been established. Localization studies correlated Le' expression and plunipotency of cells (Fox et al., 1981) , which is also suggested by its disappearance from embryonal carcinoma cells upon differentiation (Gooi et al., 1981; Pennington et al., 1985; Brown et al., 1993) .
The Le' determinant, associated with glycolipids or glycoproteins, is also found in the developing and adult CNS of a variety of organisms (Lagenaur et al., 1982; Yamamoto et al., 1985; Mai and Reiffenberger, 1988; Mai and Schönlau, 1990; Bartsch and Mai, 1991; Marani and Mai, 1992; Satoh and Kim, 1994) , showing considerable differences in distribution patterns in different species. Some of this variability might be due to the antibodies used for detection, which appear to differ in their fine specificities and tend to give variable results in similar systems (compare Gooi et al., 1985: Dodd and Jessell, 1986; Marani and Mai, 1992; Satoh and Kim, 1994) . One common feature emerging from most of the studies is the expression of the epitope on astrocytes, which was also found for the L5 epitope in the murine cerebellum (Streit et al., 1990) , where it was proposed to participate in the formation of astrocytie processes on extracellular matrix (Streit ct al., 1993) . Extensive process outgrowth of astrocytes is not only observed during normal development, but also after injury of the CNS; these reactive astroeytes were shown to reexpress the SSEA-l antigen strongly (Gocht and Löhler, 1993) . In this context, it is noteworthy that CD15 expression in immortalized astrocytes is particularly concentrated at contact sites and processes (Stark et al., 1992) , supporting the notion that Le' might indeed mediate interactions between astrocytes and the extracellular matrix.
In the chick embryo, various antibodies have been used to localize Le'/CDI5 during development, again showing different expression patterns (Dodd and Jessell, 1986; Scott, 1993) , none of which matches [5 expression exactly. Our results indicate that anti-SSEA-I (Solter and Knowles, 1978; Gooi et al., 1981) and AC4 Jessell, 1985, 1986; Yamada et al., 1991) are most closely related to the L5 antibody. Their patterns of immunoreactivity in the early embryo are almost identical, showing the presence of the Le sequence predominantly in the developing nervous system. The differences at later stages might be due to distinct fine specificities or different susceptibility of the three antibodies to substitutions. The exact motifs recognized by them are still unknown.
During embryogenesis, striking changes in the expression of other carbohydrate antigens have been described (Dodd and Jessell, 1986; Canning and Stern. 1988; Thorpe et al., 1988; Loveless et al., 1990) , some of which can be correlated with specific developmental processes. Appearance of the neural plate coincides with the loss of long-chain linear and branched type 2 antigens i (Den) and I (Step) (Thorpe et al., 1988) and the type 1 structure recognized by FCIO.2 (Loveless et al., 1990) ; whereas, at the same time, short branched chains such as sialosyl I (Ma) appear to accumulate in the presumptive neural plate. In a similar manner, lectin binding properties of the neuroectoderm change dramatically during neurulation (Curnie et al., 1984; Takahashi and Howes, 1986; Takahashi, 1988 Takahashi, , 1992 .
Up to now, very little has been known about the biological properties of these glycoconjugates during embryogenesis. Our previous studies showed that the L5 carbohydrate is present at a very early stage in neural development and it was suggested that [5 may be a marker for cells competent to respond to neural inducing signals (Streit et al., 1995) and that it plays an important role during the early steps of neural development, because antibodies to the epitope interfere with neural induction or neural plate formation (Rob-.1. Neuro, hern., Vol. 66, No. 2, /996 erts et al., 1991). The exact mechanism of L5 action still remains unclear. That we were able to identify the L5 epitope as an Le'-related sequence, which is known to participate in cell-cell interactions, raises the possibility that the [5 epitope is also involved in interactions between cells of the developing neural ectoderm. This may involve binding of a complementary ligand on the cell surface.
Underscoring the biological role of carbohydrate moieties during early neural development, it is of interest that transgenic mice deficient in N-acetylglucosaminyl transferase I show defects in development of neuroepithelial cells and closure of the neural tube (loffe and Stanley, 1994; Metzler et al., 1994) . In the future, it will be important to determine whether the defects in neural development are due to the lack of complextype N-linked chains per se on to the lack of expression of the Le' determinant.
